The effect of chemotherapy on coagulation in patients with locally advanced or metastasized pancreatic cancer

The effect of chemotherapy on coagulation in patients with locally advanced or metastasized pancreatic cancer - Effect of chemotherapy on coagulation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41433

Enrollment

Registered

2014-01-07

Start date

2014-01-29

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

"blood clotting" "coagulation"

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Ductal adenocarcinoma of the pancreas confirmed by histology or cytology • Locally advanced or metastasized disease • Planned for first line FOLFIRINOX chemotherapy with or without CCX872-B • Chemotherapy naïve • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • 18 years of age or older • Fully capable of making health related decisions • Written informed consent

Exclusion criteria

Exclusion criteria: • Current prophylactic or therapeutic anticoagulant therapy • Current use of anti-inflammatory drugs • Renal insufficiency with estimated glomerular filtration rate

Design outcomes

Primary

Measure	Time frame
- Increase of procoagulant microparticles during chemotherapy - Source of procoagulant microparticles	—

Secondary

Measure	Time frame
- Levels of coagulation markers during chemotherapy - Levels of inflammation markers during chemotherapy - Association between inflammation and coagulation	—

Countries

Netherlands

Outcome results